AIFF

Business Context and Reporting Period

Company: Firefly Neuroscience, Inc. (Nasdaq: AIFF)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2026 (Events reported through February 4, 2026)
Context: The filing discloses the entry into a material definitive agreement for an equity offering and an amendment to a key executive's employment contract.

Key Financial Metrics and Agreements

At-the-Market (ATM) Offering:

• Aggregate Sales Price: Up to $7,434,266.
• Sales Agent: Konik Capital Partners, LLC (KCP).
• Commission: 2.0% of aggregate gross proceeds.
• Legal Reimbursement: Up to $50,000 for counsel fees, plus up to $5,000 per due diligence update (capped at $20,000 per fiscal year).
• Use of Proceeds: Working capital and general corporate purposes.

Executive Compensation Adjustment:

• Executive: Gil Issachar, Chief Technology Officer.
• Change: Automatic annual bonus replaced with eligibility for a discretionary annual bonus of up to one month of gross salary.
• Accrued Obligations: Agreement provides for payment of outstanding bonuses accrued through December 31, 2025.

Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.

Material Changes Versus Prior Period

The filing does not present comparative financial data. Material changes are limited to:

• Establishment of a new equity financing mechanism (ATM Agreement) allowing for the sale of up to approximately $7.4 million in common stock.
• Modification of the CTO's compensation structure from an automatic bonus to a discretionary model, alongside the settlement of accrued bonus liabilities.

Guidance, Outlook, and Risks

Outlook: Management intends to utilize net proceeds from the ATM offering for working capital and general corporate purposes. The company has no obligation to sell shares, and the agent has no obligation to buy or sell shares; either party may suspend or terminate the agreement.

Risks and Contingencies:

• Market Risk: Sales are subject to market conditions and the discretion of the Sales Agent.
• Dilution: Issuance of shares under the ATM agreement will result in dilution to existing shareholders.
• Legal Liability: The Company has agreed to indemnify the Sales Agent against certain liabilities under the Securities Act.

Unusual Items: None reported beyond the standard terms of the ATM agreement and employment amendment.

Investor Verification Checklist

• Verify the current market price of AIFF to assess potential dilution impact from the $7.4 million ATM offering.
• Review the full text of the ATM Agreement (Exhibit 1.1) for specific covenants and termination rights.
• Confirm the exact amount of outstanding bonuses accrued through December 31, 2025, to be paid to the CTO.
• Monitor future filings for actual sales volumes and proceeds generated under the ATM program.
• Check the company's cash position in the most recent 10-Q or 10-K to understand the urgency of the working capital need.